γδ T cells for immune therapy of patients with lymphoid malignancies

Blood

Volumn 102, Issue 1, 2003, Pages 200-206

  Wilhelm, Martin ^b   Kunzmann, Volker ^a   Eckstein, Susanne ^b   Reimer, Peter ^b   Weissinger, Florian ^b   Ruediger, Thomas ^b   Tony, Hans Peter ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CARMUSTINE; CD69 ANTIGEN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOKINE; DEXAMETHASONE; ETOPOSIDE; FLUDARABINE; GAMMA INTERFERON; HLA DR ANTIGEN; IDARUBICIN; INTERLEUKIN 2; INTERLEUKIN 4; MELPHALAN; MITOXANTRONE; PAMIDRONIC ACID; PARACETAMOL; PREDNIMUSTINE; PREDNISONE; RITUXIMAB; STEROID; TUMOR NECROSIS FACTOR ALPHA; VINCRISTINE; VINDESINE; BISPHOSPHONIC ACID DERIVATIVE; LYMPHOCYTE ANTIGEN RECEPTOR;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CHILL; CLINICAL ARTICLE; DRUG INFUSION; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; FEMALE; FEVER; FLUORESCENCE ACTIVATED CELL SORTING; HEMATOPOIETIC SYSTEM TUMOR; HUMAN; HUMAN CELL; INJECTION SITE; LYMPHOCYTE PROLIFERATION; MALE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SIDE EFFECT; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; THROMBOPHLEBITIS; TREATMENT OUTCOME; VEIN THROMBOSIS; B CELL LYMPHOMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; METHODOLOGY; MIDDLE AGED; PILOT STUDY; REMISSION; SALVAGE THERAPY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PILOT PROJECTS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; REMISSION INDUCTION; SALVAGE THERAPY; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 0037968274     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-12-3665     Document Type: Article

References (33)

1. Schultze JL, Nadler LM. T cell mediated immunotherapy for B cell lymphoma. J Mol Med. 1999;77: 322-331.
2. Kim S, Iizuka K, Aguila HL, Weissman IL, Yokoyama WM. In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc Natl Acad Sci U S A. 2000;97:2731-2736.
3. Smyth MJ, Thia KY, Street SE, et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med. 2000;191:661-668.
4. Girardi M, Oppenheim DE, Steele CR, et al. Regulation of cutaneous malignancy by γδ T cells. Science. 2001;294:605-609.
5. Smyth MJ, Godfrey DI, Trapani JA. Afresh look at tumor immunosurveillance and immunotherapy. Nat Immunol. 2001;2:293-299.
6. Groh V, Steinle A, Bauer S, Spies T. Recognition of stress-induced MHC molecules by intestinal epithelial γδ T cells. Science. 1998;279:1737-1740.
7. Fisch P, Meuer E, Pende D, et al. Control of B cell lymphoma recognition via natural killer inhibitory receptors implies a role for human Vγ9/Vδ2 T cells in tumor immunity. Eur J Immunol. 1997;27: 3368-3379.
8. Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M. Stimulation of γδ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood. 2000;96:384-392.
9. Sicard H, Al Saati T, Delsol G, Fournie JJ. Synthetic phosphoantigens enhance human Vγ9Vδ2 T lymphocytes killing of non-Hodgkin's B lymphoma. Mol Med. 2001;7:711-722.
10. Kato Y, Tanaka Y, Miyagawa F, Yamashita S, Minato N. Targeting of tumor cells for human γδ T cells by nonpeptide antigens. J Immunol, 2001; 167:5092-5098.
11. + T cells in disease-free survivors following T cell-depleted, partially mismatched, related donor bone marrow transplantation for leukemia. J Hematother. 1996; 5:503-509.
12. Zheng BJ, Chan KW, Im S, et al. Anti-tumor effects of human peripheral γδ T cells in a mouse tumor model. Int J Cancer. 2001;92:421-425.
13. Tanaka Y, Morita CT, Nieves E, Brenner MB, Bloom BR. Natural and synthetic non-peptide antigens recognized by human γδ T cells. Nature. 1995;375:155-158.
14. Constant P, Davodeau F, Peyrat MA, et al. Stimulation of human γδ T cells by nonpeptidic mycobacterial ligands. Science. 1994;264:267-270.
15. Jomaa H, Feurle J, Luhs K, et al. Vγ9/Vδ2 T cell activation induced by bacterial low molecular mass compounds depends on the 1-deoxy-D-xylulose 5-phosphate pathway of isoprenoid biosynthesis. FEMS Immunol Med Microbiol. 1999; 25:371-378.
16. Feurle J, Eckstein S, Espinosa E, et al. E. coli phosphoantigens acitvating γδ T cells. J Biol Chem. 2001;277:148-154.
17. Bukowski JF, Morita CT, Brenner MB. Human γδ T cells recognize alkylamines derived from microbes, edible plants, and tea: implications for innate immunity. Immunity. 1999;11:57-65.
18. Kunzmann V, Bauer E, Wilhelm M. γ/δ T-cell stimulation by pamidronate [letter]. N Engl J Med. 1999;340:737-738.
19. Morita CT, Beckman EM, Bukowski JF, et al. Direct presentation of nonpeptide prenyl pyrophosphate antigens to human γδ T cells. Immunity. 1995;3:495-507.
20. Gucalp R, Ritch P, Wiernik PH, et al. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. J Clin Oncol. 1992;10:134-142.
21. Glover D, Lipton A, Keller A, et al. Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer: a dose-seeking study. Cancer. 1994;74:2949-2955.
22. Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther. 2002; 302:1055-1061.
23. Das H, Wang L, Kamath A, Bukowski JF. Vγ2Vδ2 T-cell receptor-mediated recognition of aminobisphosphonates. Blood. 2001;98:1616-1618.
24. Miyagawa F, Tanaka Y, Yamashita S, et al. Essential contribution of germline-encoded lysine residues in Jγ1.2 segment to the recognition of non-peptide antigens by human γδ T cells. J Immunol. 2001;167:6773-6779.
25. Whittington R, Faulds D. Interleukin-2: a review of its pharmacological properties and therapeutic use in patients with cancer. Drugs. 1993;46:446-514.
26. Weber JS, Yang JC, Topalian SL, Schwartzentruber DJ, White DE, Rosenberg SA. The use of interleukin-2 and lymphokine-activated killer cells for the treatment of patients with non-Hodgkin's lymphoma. J Clin Oncol. 1992;10:33-40.
27. Peest D, Leo R, Bloche S, et al. Low-dose recombinant interleukin-2 therapy in advanced multiple myeloma. Br J Haematol. 1995;89:328-337.
28. Moris A, Rothenfusser S, Meuer E, Hangretinger R, Fisch P. Role of γδ T cells in tumor immunity and their control by NK receptors. Microbes Infect. 1999;1:227-234.
29. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature. 2001;413: 165-171.
30. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature. 2001;411:375-379.
31. Miyagawa F, Tanaka Y, Yamashita S, Minato N. Essential requirement of antigen presentation by monocyte lineage cells for the activation of primary human γδ T cells by aminobisphosphonate antigen. J Immunol. 2001;166:5508-5514.
32. Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-γ. Annu Rev Immunol. 1997;15:749-795.
33. Santini D, Vincenzi B, Avvisati G, et al. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res. 2002;8:1080-1084.